시장보고서

상품코드

1455671

마이크로바이옴 치료제 시장 : 제품 유형별, 용도별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Microbiome Therapeutics Market, By Product Type, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 03월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 322 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

미생물체 치료제 시장 규모는 2023년 1억 245만 달러로 평가되었고, 2024년부터 2032년까지 연평균 36.78% 성장할 것으로 예상됩니다.

마이크로바이옴 치료제 시장 - 시장 역학

마이크로바이옴 연구의 발전은 시장 수요를 촉진합니다.

개발 중인 대부분의 치료제는 초기 단계에 있으며, 보통 1상 및 2상 단계에 있습니다. 소화기(GI) 적응증은 23개 품목 중 13개 이상의 품목이 연구 중이며, 대부분 궤양성 대장염에 초점을 맞추었습니다. 예를 들어, 세레스 테라퓨틱스는 2021년 재발성 C. difficile 감염을 대상으로 한 경구용 치료제 SER-109의 ECOSPOR III 임상 3상 데이터를 발표했으며, 2023년 상반기 출시를 목표로 하고 있습니다. 주목할 만한 점은 SER-109가 위약 대비 항균제 내성 유전자의 감소와 관련이 있다는 것입니다. 마이크로바이옴 연구의 발전은 감염 및 기타 질병에 대한 개선된 치료법 발견을 촉진하고 의료 성과를 향상시킬 것으로 기대됩니다. 마이크로바이옴 기반 치료법의 채택을 촉진하기 위해 기업들은 제품 비용을 낮추고 더 많은 사람들이 첨단 의료에 대한 접근성을 확대하기 위해 노력하고 있습니다. 또한, 여러 정부 기관이 접근 방식을 재구성하고 있습니다. 그 결과, 시장 공급업체들은 시장 점유율을 확대할 수 있는 유리한 성장 기회를 얻게 되었습니다.

마이크로바이옴 치료제 시장 - 주요 인사이트

세계 시장은 예측 기간(2024-2032년) 동안 매년 약 36.78%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.

제품 유형별로는 FMT가 2023년 가장 큰 시장 점유율을 보일 것으로 예상됩니다.

용도별로는 2023년 C. difficile이 주요 유형이었습니다.

지역별로는 북미가 2023년에 가장 큰 수익을 창출할 주요 시장입니다.

마이크로바이옴 치료제 시장 - 세분화 분석 :

마이크로바이옴 치료제 세계 시장은 제품 유형, 용도, 지역에 따라 세분화됩니다.

시장은 제품 유형에 따라 FMT와 마이크로바이옴 치료제의 두 가지 범주로 나뉘며, 2023년에는 분변 미생물총 요법(FMT)이 마이크로바이옴 치료제 시장의 지배적 인 힘으로 부상했습니다. 이러한 우위는 주로 C. difficile 감염 치료에 널리 사용되고 있기 때문입니다. 또한, FMT의 새로운 치료 용도를 모색하기 위한 연구 개발에 대한 관심이 높아지고 캡슐이 시장에 출시되면서 FMT의 성장을 가속할 것으로 예상됩니다. 예를 들어, 2021년 2월 오픈바이옴(OpenBiome)은 분변 미생물총 치료제에서 SARS-COV-2에 대한 새로운 직접 검사를 도입하여 감염 전파의 위험을 줄이면서 긴급 사용을 위해 예정된 환자들에게 FMT의 가용성을 높이는 것을 목표로 하고 있습니다.

시장은 용도별로 C. difficile, 크론병, 크론병, 염증성 장질환, 당뇨병, 기타 등 5개 카테고리로 분류됩니다. 클로스트리듐 디피실 감염증(CDI 또는 C. difficile) 관련 부문은 2023년에도 시장 지배력을 유지할 것으로 예상됩니다. 이 부문의 확대는 C. difficile 감염 치료를 위한 분변 미생물총 이식(FMT)의 채택이 증가하고 있기 때문입니다. 버밍엄 대학교에서 실시한 2020년 연구에 따르면, FMT는 클로스트리듐 디피실 감염 환자 치료에 널리 사용되고 있습니다. 또한 FMT는 항생제에 비해 C. difficile 치료에 더 높은 효능을 보였으며, 특히 재발 사례에서 더 높은 효능을 보여주었습니다.

마이크로바이옴 치료제 시장 - 지리적 인사이트

지리적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에 분포되어 있습니다. 이 지역은 비즈니스를 가져 오는 국가에 따라 더 세분화됩니다.

마이크로바이옴 치료제 시장 - 경쟁상황:

마이크로바이옴 치료제 시장의 기업들은 경쟁력을 유지하기 위해 연구 개발에 투자하여 새로운 치료 용도를 탐색하고, 제품의 접근성과 가격을 개선하고, 연구 기관 및 의료 서비스 제공업체와의 협력 관계를 촉진하고, 기술 발전을 활용하여 제품의 효능과 안전성을 향상시키는 등 다양한 전략을 구사하고 있다, 다양한 전략을 채택하고 있습니다. 이러한 전략은 기술 혁신을 촉진하고 시장 진입을 확대하며 궁극적으로 미생물 기반 치료 분야에서 환자 치료 결과를 개선하는 것을 목표로 합니다.

서론
북미
- 개요
- 북미 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양
- 개요
- 아시아태평양 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제10장 주요 벤더 분석 : 마이크로바이옴 치료제 산업

경쟁 대시보드
기업 개요
- OpenBiome
- Seres Therapeutics Inc.
- D Pharma plc.
- Locus Biosciences, Inc.
- Enterome SA
- Finch Therapeutics Group, Inc.
- Intralytix, Inc.
- Microbiotica
- Second Genome
- Rebiotix Inc.
- Vedanta Bioscience, Inc.
- Others

제11장 애널리스트의 전방위 전망

LSH 24.04.03

REPORT HIGHLIGHT

Microbiome therapeutics Market size was valued at USD 102.45 Million in 2023, expanding at a CAGR of 36.78% from 2024 to 2032.

Microbiome therapeutics entail the development and application of treatments directed at the human microbiome, which comprises a complex community of microorganisms residing within the human body. These therapeutics are designed to restore, manipulate, or enhance microbial balance within the body, thereby fostering health and addressing various medical conditions. They manifest in different forms, including probiotics (live beneficial bacteria), prebiotics (substances promoting the growth of beneficial bacteria), postbiotics (metabolites produced by beneficial bacteria), and fecal microbiota transplantation (the transfer of fecal matter from a healthy donor to a recipient).

Microbiome therapeutics Market- Market Dynamics

Advancements in microbiome research to propel market demand

The majority of therapeutic agents in development are in the early stages, typically Phase I and Phase II. Regarding gastrointestinal (GI) indications, over 13 drugs out of 23 are under investigation, with the majority focusing on ulcerative colitis. For example, in 2021, Seres Therapeutics, Inc. introduced data from its Phase 3 ECOSPOR III study on SER-109, an oral therapy investigated for recurrent C. difficile infection, with an anticipated launch slated for the first half of 2023. Notably, compared to the placebo, SER-109 is associated with a decrease in antimicrobial resistance genes. Advancements in microbiome research are expected to facilitate the discovery of improved treatments for infections and other diseases, thereby enhancing medical care outcomes. To promote the adoption of microbiome-based treatments, companies are reducing the cost of their products and expanding access to cutting-edge medical care to a broader segment of the population. Additionally, several governing bodies are restructuring their approaches. Consequently, this presents market vendors with lucrative growth opportunities to enhance their market share.

Microbiome therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 36.78% over the forecast period (2024-2032)

Based on Product Type segmentation, FMT was predicted to show maximum market share in the year 2023

Based on Application segmentation, C. difficile was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Microbiome therapeutics Market- Segmentation Analysis:

The Global Microbiome therapeutics Market is segmented on the basis of Product Type, Application, and Region.

The market is divided into two categories based on Product Type: FMT and Microbiome Drugs. In 2023, Fecal Microbiota Therapy (FMT) emerged as the dominant force in the microbiome therapeutics market. This dominance is primarily ascribed to its extensive utilization in treating C. difficile infection. Additionally, the growing focus on research and development aimed at exploring alternative therapeutic applications of FMT, coupled with the introduction of capsules into the market, is anticipated to propel its growth. For instance, in February 2021, OpenBiome announced the introduction of new direct testing for SARS-COV-2 in fecal microbiota therapy preparations, aiming to enhance FMT availability to scheduled patients for emergency use while mitigating the risk of infection transmission.

The market is divided into five categories based on Application: C. difficile, Crohn's disease, Inflammatory Bowel Disease, Diabetes and Others. The application segment pertaining to Clostridium difficile infection (CDI or C. difficile) is forecasted to maintain dominance in the market in 2023. The expansion of this segment is attributed to the increasing adoption of Fecal Microbiota Transplants (FMT) for treating C. difficile infections. According to a 2020 study conducted by the University of Birmingham, FMT is widely accepted for treating patients afflicted with Clostridium difficile infections. Furthermore, FMT demonstrates greater efficacy in treating C. difficile compared to antibiotics, particularly in cases of recurrence.

Microbiome therapeutics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Microbiome therapeutics Market- Competitive Landscape:

Companies in the microbiome therapeutics market employ various strategies to stay competitive, including investing in research and development to explore new therapeutic applications, enhancing product accessibility and affordability, fostering collaborations with research institutions and healthcare providers, and leveraging technological advancements to improve product efficacy and safety. These strategies aim to drive innovation, expand market reach, and ultimately improve patient outcomes in the field of microbiome-based therapies.

Recent Developments:

In December 2021, Kaleido Biosciences revealed a partnership with Janssen to explore the efficacy of microbiome metabolic therapies in preventing immune, atopic, and metabolic conditions that emerge in childhood.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MICROBIOME THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT

OpenBiome

Seres Therapeutics Inc.

4D Pharma plc.

Locus Biosciences, Inc.

Enterome SA

Finch Therapeutics Group, Inc.

Intralytix, Inc.

Microbiotica

Second Genome

Rebiotix Inc.

Vedanta Bioscience, Inc.

Others

GLOBAL MICROBIOME THERAPEUTICS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

FMT
Microbiome Drugs

GLOBAL MICROBIOME THERAPEUTICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

C. difficile
Crohn's disease
Inflammatory Bowel Disease
Diabetes
Others

GLOBAL MICROBIOME THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1.Microbiome therapeutics Market Overview

1.1.Study Scope
1.2.Market Estimation Years

2.Executive Summary

2.1.Market Snippet
- 2.1.1.Microbiome therapeutics Market Snippet by Product Type
- 2.1.2.Microbiome therapeutics Market Snippet by Application
- 2.1.3.Microbiome therapeutics Market Snippet by Country
- 2.1.4.Microbiome therapeutics Market Snippet by Region
2.2.Competitive Insights

3.Microbiome therapeutics Key Market Trends

3.1.Microbiome therapeutics Market Drivers
- 3.1.1.Impact Analysis of Market Drivers
3.2.Microbiome therapeutics Market Restraints
- 3.2.1.Impact Analysis of Market Restraints
3.3.Microbiome therapeutics Market Opportunities
3.4.Microbiome therapeutics Market Future Trends

4.Microbiome therapeutics Industry Study

4.1.PEST Analysis
4.2.Porter's Five Forces Analysis
4.3.Growth Prospect Mapping
4.4.Regulatory Framework Analysis

5.Microbiome therapeutics Market: COVID-19 Impact Analysis

5.1.Pre-COVID-19 Impact Analysis
5.2.Post-COVID-19 Impact Analysis
- 5.2.1.Top Performing Segments
- 5.2.2.Marginal Growth Segments
- 5.2.3.Top Looser Segments
- 5.2.4.Marginal Loss Segments

6.Microbiome therapeutics Market Landscape

6.1.Microbiome therapeutics Market Share Analysis, 2023
6.2.Breakdown Data, by Key Manufacturer
- 6.2.1.Established Players' Analysis
- 6.2.2.Emerging Players' Analysis

7.Microbiome therapeutics Market - By Product Type

7.1.Overview
- 7.1.1.Segment Share Analysis, By Product Type, 2023 & 2032 (%)
- 7.1.2.FMT
- 7.1.3.Microbiome Drugs

8.Microbiome therapeutics Market - By Application

8.1.Overview
- 8.1.1.Segment Share Analysis, By Application, 2023 & 2032 (%)
- 8.1.2.C. difficile
- 8.1.3.Crohn's disease
- 8.1.4.Inflammatory Bowel Disease
- 8.1.5.Diabetes
- 8.1.6.Others

9.Microbiome therapeutics Market- By Geography

9.1.Introduction
- 9.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
9.2.North America
- 9.2.1.Overview
- 9.2.2.Microbiome therapeutics Key Manufacturers in North America
- 9.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.2.4.North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 9.2.5.North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.2.6.U.S.
  - 9.2.6.1.Overview
  - 9.2.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.6.3.U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.2.6.4.U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.2.7.Canada
  - 9.2.7.1.Overview
  - 9.2.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.7.3.Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.2.7.4.Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
9.3.Europe
- 9.3.1.Overview
- 9.3.2.Microbiome therapeutics Key Manufacturers in Europe
- 9.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.3.4.Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 9.3.5.Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.6.Germany
  - 9.3.6.1.Overview
  - 9.3.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.6.3.Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.6.4.Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.7.Italy
  - 9.3.7.1.Overview
  - 9.3.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.7.3.Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.7.4.Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.8.United Kingdom
  - 9.3.8.1.Overview
  - 9.3.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.8.3.United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.8.4.United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.9.France
  - 9.3.9.1.Overview
  - 9.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.9.3.France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.9.4.France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.10.Russia
  - 9.3.10.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.10.2.Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.10.3.Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.11.Netherlands
  - 9.3.11.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.11.2.Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.11.3.Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.12.Sweden
  - 9.3.12.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.12.2.Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.12.3.Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.13.Poland
  - 9.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.13.2.Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.13.3.Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.14.Rest of Europe
  - 9.3.14.1.Overview
  - 9.3.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.14.3.Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.14.4.Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
9.4.Asia Pacific (APAC)
- 9.4.1.Overview
- 9.4.2.Microbiome therapeutics Key Manufacturers in Asia Pacific
- 9.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.4.4.Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 9.4.5.Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.6.India
  - 9.4.6.1.Overview
  - 9.4.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.6.3.India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.6.4.India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.7.China
  - 9.4.7.1.Overview
  - 9.4.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.7.3.China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.7.4.China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.8.Japan
  - 9.4.8.1.Overview
  - 9.4.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.8.3.Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.8.4.Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.9.South Korea
  - 9.4.9.1.Overview
  - 9.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.9.3.South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.9.4.South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.10.Australia
  - 9.4.10.1.Overview
  - 9.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.10.3.Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.10.4.Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.11.Thailand
  - 9.4.11.1.Overview
  - 9.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.11.3.Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.11.4.Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.12.Indonesia
  - 9.4.12.1.Overview
  - 9.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.12.3.Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.12.4.Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.13.Philippines
  - 9.4.13.1.Overview
  - 9.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.13.3.Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.13.4.Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.14.Rest of APAC
  - 9.4.14.1.Overview
  - 9.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.14.3.Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.14.4.Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
9.5.Latin America
- 9.5.1.Overview
- 9.5.2.Microbiome therapeutics Key Manufacturers in Latin America
- 9.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.5.4.Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 9.5.5.Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.6.Brazil
  - 9.5.6.1.Overview
  - 9.5.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.6.3.Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.5.6.4.Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.7.Mexico
  - 9.5.7.1.Overview
  - 9.5.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.7.3.Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.5.7.4.Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.8.Argentina
  - 9.5.8.1.Overview
  - 9.5.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.8.3.Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.5.8.4.Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.9.Colombia
  - 9.5.9.1.Overview
  - 9.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.9.3.Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.5.9.4.Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.10.Rest of LATAM
  - 9.5.10.1.Overview
  - 9.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.10.3.Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.5.10.4.Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
9.6.Middle East and Africa
- 9.6.1.Overview
- 9.6.2.Microbiome therapeutics Key Manufacturers in Middle East and Africa
- 9.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.6.4.Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 9.6.5.Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.6.Saudi Arabia
  - 9.6.6.1.Overview
  - 9.6.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.6.3.Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.6.4.Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.7.United Arab Emirates
  - 9.6.7.1.Overview
  - 9.6.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.7.3.United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.7.4.United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.8.Israel
  - 9.6.8.1.Overview
  - 9.6.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.8.3.Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.8.4.Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.9.Turkey
  - 9.6.9.1.Overview
  - 9.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.9.3.Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.9.4.Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.10.Algeria
  - 9.6.10.1.Overview
  - 9.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.10.3.Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.10.4.Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.11.Egypt
  - 9.6.11.1.Overview
  - 9.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.11.3.Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.11.4.Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.12.Rest of MEA
  - 9.6.12.1.Overview
  - 9.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.12.3.Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.12.4.Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

10.Key Vendor Analysis- Microbiome therapeutics Industry

10.1.Competitive Dashboard
10.2.Company Profiles
- 10.2.1.OpenBiome
- 10.2.2.Seres Therapeutics Inc.
- 10.2.3.4D Pharma plc.
- 10.2.4.Locus Biosciences, Inc.
- 10.2.5.Enterome SA
- 10.2.6.Finch Therapeutics Group, Inc.
- 10.2.7.Intralytix, Inc.
- 10.2.8.Microbiotica
- 10.2.9.Second Genome
- 10.2.10.Rebiotix Inc.
- 10.2.11.Vedanta Bioscience, Inc.
- 10.2.12.Others

11.360 Degree Analyst View

12.Appendix

12.1.Research Methodology
12.2.References
12.3.Abbreviations
12.4.Disclaimer
12.5.Contact Us